MT-CO1 and tuberculosis: In this regard, leading stakeholders have suggested to repurpose broadly used drugs like non-steroidal anti-inflammatory drugs (NSAIDs), including cyclooxygenase inhibitors (COX-i), as adjunctive to standard TB treatment.